نتائج البحث

First-line treatment of EGFR-mutated non-small cell lung cancer with brain metastases: a systematic review and meta-analysis.

• Authors : Ma J; Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, 110004, China.; Department of Medical Oncology, Second Clinical College of China Medical University, Shenyang, 110022, China.

Subjects: Brain Neoplasms*/Brain Neoplasms*/Brain Neoplasms*/drug therapy ; Brain Neoplasms*/Brain Neoplasms*/Brain Neoplasms*/genetics ; Brain Neoplasms*/Brain Neoplasms*/Brain Neoplasms*/mortality

• Source: Scientific reports [Sci Rep] 2024 Oct 02; Vol. 14 (1), pp. 22901. Date of Electronic Publication: 2024 Oct 02.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

Outcomes of first-line treatment and their association with pretreatment neutrophil-to-lymphocyte ratio in patients with advanced renal cell carcinoma: Insights from a tertiary care institute in Pakistan.

• Authors : Samar MR; Medical Oncology, Department of Oncology, The Aga Khan University, Karachi 74600, Pakistan.; Javaid M

• Source: Ecancermedicalscience [Ecancermedicalscience] 2024 Sep 03; Vol. 18, pp. 1753. Date of Electronic Publication: 2024 Sep 03 (Print Publication: 2024).Publisher: ecancer Country of Publication: England NLM ID: 101392236 Publication Model: eCollection Cited Medium: Print ISSN: 1754-6605 (Print)

تفاصيل العنوان

Clinical efficacy and safety of first-line nilotinib or imatinib therapy in patients with chronic myeloid leukemia-Nationwide real life data.

• Authors : Belohlavkova P; 4th Department of Internal Medicine and Haematology, University Hospital Hradec Kralove and Charles University, Prague, Czech Republic.; Zackova D

Subjects: Imatinib Mesylate*/Imatinib Mesylate*/Imatinib Mesylate*/therapeutic use ; Imatinib Mesylate*/Imatinib Mesylate*/Imatinib Mesylate*/adverse effects ; Pyrimidines*/Pyrimidines*/Pyrimidines*/therapeutic use

• Source: Cancer medicine [Cancer Med] 2024 Sep; Vol. 13 (17), pp. e70158.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN:

تفاصيل العنوان

First-line treatment with gefitinib in combination with bevacizumab and chemotherapy in advanced non-squamous NSCLC with EGFR-mutation.

• Authors : Xiong Y; Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, China.; Tianjin's Clinical Research Center for Cancer, Tianjin, China.

Subjects: Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/drug therapy ; Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/genetics ; Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/pathology

• Source: BMC cancer [BMC Cancer] 2024 Oct 29; Vol. 24 (1), pp. 1326. Date of Electronic Publication: 2024 Oct 29.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

تفاصيل العنوان

Prognostic potential of standard laboratory parameters in patients with metastatic renal cell cancer receiving first-line immunotherapy.

• Authors : Buerk BT; Department of Urology, Faculty of Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.; Kusiek C

Subjects: Carcinoma, Renal Cell*/Carcinoma, Renal Cell*/Carcinoma, Renal Cell*/drug therapy ; Carcinoma, Renal Cell*/Carcinoma, Renal Cell*/Carcinoma, Renal Cell*/mortality ; Carcinoma, Renal Cell*/Carcinoma, Renal Cell*/Carcinoma, Renal Cell*/pathology

• Source: Scientific reports [Sci Rep] 2024 Oct 25; Vol. 14 (1), pp. 25365. Date of Electronic Publication: 2024 Oct 25.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

Overall Survival in Real-World Patients with Unresectable Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab Versus Sorafenib or Lenvatinib as First-Line Therapy: Findings from the National Veterans Health Administration Database.

• Authors : Kaplan DE; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.; Gastroenterology Section, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA 19104, USA.

• Source: Cancers [Cancers (Basel)] 2024 Oct 17; Vol. 16 (20). Date of Electronic Publication: 2024 Oct 17.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print)

تفاصيل العنوان

Efficacy analysis of HAIC combined with lenvatinib plus PD1 inhibitor vs. first-line systemic chemotherapy for advanced intrahepatic cholangiocarcinoma.

• Authors : Lin Z; Department of Interventonal Medicine, Zhongshan People's Hospital, Guangdong, 528400, China.; Zou X

Subjects: Cholangiocarcinoma*/Cholangiocarcinoma*/Cholangiocarcinoma*/drug therapy ; Cholangiocarcinoma*/Cholangiocarcinoma*/Cholangiocarcinoma*/pathology ; Quinolines*/Quinolines*/Quinolines*/therapeutic use

• Source: Scientific reports [Sci Rep] 2024 Oct 14; Vol. 14 (1), pp. 23961. Date of Electronic Publication: 2024 Oct 14.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

The outcome of advanced and recurrent cervical cancer patients treated with first-line platinum and paclitaxel with or without indication for immune checkpoint inhibitors: the comparative study.

• Authors : Feng L; Department of Gynecology, The First Affiliated Hospital of Xingtai Medical College, Xingtai, 054000, China.; Shi Q

Subjects: Uterine Cervical Neoplasms*/Uterine Cervical Neoplasms*/Uterine Cervical Neoplasms*/drug therapy ; Uterine Cervical Neoplasms*/Uterine Cervical Neoplasms*/Uterine Cervical Neoplasms*/mortality ; Uterine Cervical Neoplasms*/Uterine Cervical Neoplasms*/Uterine Cervical Neoplasms*/pathology

• Source: BMC cancer [BMC Cancer] 2024 Oct 11; Vol. 24 (1), pp. 1267. Date of Electronic Publication: 2024 Oct 11.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

تفاصيل العنوان

Impact of systemic steroids on the efficacy of first line imatinib treatment of patients with advanced gastrointestinal stromal tumors (GISTs).

• Authors : Kim S; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.; Kim HD

Subjects: Gastrointestinal Stromal Tumors*/Gastrointestinal Stromal Tumors*/Gastrointestinal Stromal Tumors*/drug therapy ; Gastrointestinal Stromal Tumors*/Gastrointestinal Stromal Tumors*/Gastrointestinal Stromal Tumors*/mortality ; Gastrointestinal Stromal Tumors*/Gastrointestinal Stromal Tumors*/Gastrointestinal Stromal Tumors*/pathology

• Source: BMC cancer [BMC Cancer] 2024 Oct 08; Vol. 24 (1), pp. 1245. Date of Electronic Publication: 2024 Oct 08.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

تفاصيل العنوان

Efficacy of Levetiracetam vs Phenobarbital as First Line Therapy for the Treatment of Neonatal Seizures.

• Authors : Long D; Department of Pharmacy, Vanderbilt University Medical Center, Nashville, TN.; Sutton C

• Source: The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG [J Pediatr Pharmacol Ther] 2024 Oct; Vol. 29 (5), pp. 482-486. Date of Electronic Publisher: Pediatric Pharmacology Advocacy Group, Inc Country of Publication: United States NLM ID: 101089851 Publication Model: Print-Electronic Cited

تفاصيل العنوان